EGFR–TKI-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients With Non–Small Cell Lung Cancer

IMPORTANCE: Nivolumab and epidermal growth factor receptor–tyrosine kinase inhibitors (EGFR-TKIs) are now the standard-of-care therapies in non–small cell lung cancer (NSCLC). Although EGFR-TKIs are well understood and have well-defined safety profiles, our experience with immune checkpoint inhibito...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:JAMA Oncol
Main Authors: Oshima, Yasuo, Tanimoto, Tetsuya, Yuji, Koichiro, Tojo, Arinobu
Format: Artigo
Jezik:Inglês
Izdano: American Medical Association 2018
Teme:
Brief Report
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5885195/
https://ncbi.nlm.nih.gov/pubmed/29327061
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2017.4526
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki